C12N 9/22
Ribonucleases [rnase]
Official title: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
C12N9/22 (Ribonucleases [rnase]) appears on 4,295 US grants and 9,885 published applications in this corpus.
Search patents in C12N- Granted patents
- 4,295
- Published applications
- 9,885
- Assignees
- 2,213
- Inventors
- 14,106
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 1 | 0 |
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 4 | 0 |
| 1988 | 4 | 0 |
| 1989 | 6 | 0 |
| 1990 | 11 | 0 |
| 1991 | 20 | 0 |
| 1992 | 17 | 0 |
| 1993 | 28 | 0 |
| 1994 | 27 | 0 |
| 1995 | 21 | 0 |
| 1996 | 22 | 0 |
| 1997 | 27 | 0 |
| 1998 | 48 | 0 |
| 1999 | 50 | 0 |
| 2000 | 35 | 0 |
| 2001 | 47 | 8 |
| 2002 | 44 | 38 |
| 2003 | 33 | 73 |
| 2004 | 24 | 66 |
| 2005 | 24 | 67 |
| 2006 | 41 | 77 |
| 2007 | 27 | 56 |
| 2008 | 36 | 52 |
| 2009 | 32 | 71 |
| 2010 | 40 | 82 |
| 2011 | 43 | 109 |
| 2012 | 50 | 107 |
| 2013 | 56 | 109 |
| 2014 | 75 | 171 |
| 2015 | 69 | 178 |
| 2016 | 108 | 251 |
| 2017 | 118 | 281 |
| 2018 | 137 | 472 |
| 2019 | 198 | 636 |
| 2020 | 294 | 767 |
| 2021 | 320 | 831 |
| 2022 | 419 | 927 |
| 2023 | 431 | 1071 |
| 2024 | 438 | 1280 |
| 2025 | 505 | 1195 |
| 2026 | 354 | 910 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Prime editor system for in vivo genome editing6 Oct 2026US 12,753,397 B2University of Massachusetts
- CRISPR-mediated directed codon re-write6 Oct 2026US 12,753,398 B2Limagrain Europe S.A.
- CAS12B enzymes and systems6 Oct 2026US 12,753,406 B2Massachusetts Institute of Technology
- Compositions and methods for modifying a target nucleic acid6 Oct 2026US 12,753,412 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Methods of preventing on-target genotoxicity induced by nucleases8 Oct 2026US 2026/0306552 A1Chu De Bordeaux
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Transcription factor 4 gene editing system8 Oct 2026US 2026/0306671 A1The Regents of the University of California
- Targeting gpatch8 for treating sf3b1-mutant cancers8 Oct 2026US 2026/0306672 A1Fred Hutchinson Cancer Center
Most cited
By later US patents
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains568US 8,993,233 B2Massachusetts Institute of Technology · 2015
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014